Evidence map›Paper›PMID 28074618›Full record

ReviewAlimentary pharmacology & therapeutics2017

Review article: dose optimisation of infliximab for acute severe ulcerative colitis.

P Hindryckx, G Novak, N Vande Casteele, D Laukens, C Parker, L M Shackelton, N Narula, R Khanna, P Dulai, B G Levesque and 4 more

Open access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Alimentary pharmacology & therapeutics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed, 1 pooled it
9.9field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 1 synthesis or guideline pooled it, 92 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Refractory Crohn's Disease: Perspectives, Unmet Needs and Innovations.Clinical and experimental gastroenterology · 2024
    Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Baseline Clearance of Infliximab Is Associated With Requirement for Colectomy in Patients With Acute Severe Ulcerative Colitis.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2021
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 6 countries.

P HindryckxRobarts Clinical Trials Inc., University of Western Ontario, London, Ontario, Canada.
G NovakRobarts Clinical Trials Inc., University of Western Ontario, London, Ontario, Canada.
N Vande CasteeleRobarts Clinical Trials Inc., University of Western Ontario, London, Ontario, Canada.
D LaukensDepartment of Gastroenterology, University of Ghent, Ghent, Belgium.
C ParkerRobarts Clinical Trials Inc., University of Western Ontario, London, Ontario, Canada.
L M ShackeltonRobarts Clinical Trials Inc., University of Western Ontario, London, Ontario, Canada.
N NarulaDepartment of Medicine and Farncombe Family Digestive Health Research Institute, Division of Gastroenterology, McMaster University, Hamilton, Ontario, Canada.
R KhannaRobarts Clinical Trials Inc., University of Western Ontario, London, Ontario, Canada.
P DulaiDivision of Gastroenterology, University of California San Diego, La Jolla, California, USA.
B G LevesqueRobarts Clinical Trials Inc., University of Western Ontario, London, Ontario, Canada.
W J SandbornRobarts Clinical Trials Inc., University of Western Ontario, London, Ontario, Canada.
G D'HaensRobarts Clinical Trials Inc., University of Western Ontario, London, Ontario, Canada.
B G FeaganRobarts Clinical Trials Inc., University of Western Ontario, London, Ontario, Canada.
V JairathRobarts Clinical Trials Inc., University of Western Ontario, London, Ontario, Canada.
Robarts Clinical Trials · CAUniversity of California San Diego · USWestern University · CAGhent University · BEPopulation Health Research Institute · CA

Funding

Training Grant in GastroenterologyT32DK007202 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI GHOSH, PRADIPTA · 1985 to 2022
$7.7M
NIDDK NIH HHS T32 DK007202
6 · The paper itself

Abstract

backgroundAlthough optimal medical management of acute severe ulcerative colitis (UC) is ill-defined, infliximab has become a standard of care. Accumulating evidence suggests an increased rate of infliximab clearance in patients with acute severe UC and a reduced colectomy rate with an intensified infliximab induction regimen.

aimTo assess the strength of the current evidence for the relationship between infliximab pharmacokinetics, dosing strategies and disease behaviour in patients with acute severe UC.

methodsWe systematically searched MEDLINE and conference proceedings from 2000 to 2016 for relevant articles describing the pharmacokinetics of infliximab in acute severe UC and/or infliximab dose intensification strategies in acute severe UC. Eligible articles described randomised controlled trials, and cohort, cross-sectional, and case-controlled studies.

resultsOf 400 citations identified, 76 studies were eligible. Increased infliximab clearance occurs in patients with acute severe UC, and is driven by the total inflammatory burden and leakage of drug into the colonic lumen. Several cohort studies suggest that infliximab dose intensification is beneficial to at least 50% of acute severe UC patients and the results of case-controlled studies indicate that an intensified infliximab dosing regimen with 1-2 additional infusions in the first 3 weeks of treatment could reduce the early (3-month) colectomy rate by up to 80%, although these data require prospective validation.

conclusionsUncontrolled studies suggest a benefit for infliximab dose optimisation in patients with acute severe UC. A randomised controlled trial in acute severe UC patients comparing a personalised infliximab dose-optimisation strategy with conventional dosing is a research priority.

Indexed as

Antibodies, MonoclonalColectomyColitis, UlcerativeHumansInfliximabRandomized Controlled Trials as TopicTreatment OutcomeAntibodies, MonoclonalInfliximab

Identifiers

PMID28074618
PMCPMC6658182
OpenAlexW2574762966

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.